{
    "clinical_study": {
        "@rank": "85760", 
        "arm_group": [
            {
                "arm_group_label": "Rebif\u00ae Rebidose\u00ae/Rebiject II\u00ae", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Rebiject II\u00ae/Rebif\u00ae Rebidose\u00ae", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 4, prospective, open-label, randomized, cross-over, multicenter trial to\n      evaluate ease-of-use with Rebif\u00ae Rebidose\u00ae and Rebiject II\u00ae autoinjectors in subjects with\n      relapsing remitting multiple sclerosis (RRMS). Subjects will participate in the study for up\n      to 10 weeks (including screening and treatment periods). The treatment period will last 8\n      weeks and include 12 self-injections using the Rebif\u00ae Rebidose\u00ae device and 12\n      self-injections using the Rebiject II\u00ae device."
        }, 
        "brief_title": "Rebif\u00ae Rebidose\u00ae Versus Rebiject II\u00ae Ease-of-Use", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis, Relapsing-Remitting", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects, 18 to 65 years of age inclusive, at the time of informed\n             consent signature\n\n          -  Diagnosis of RRMS\n\n          -  Receiving Rebif\u00ae, 44 microgram subcutaneously three times a week, by manual injection\n             for at least 12 weeks before the screening assessment and previous use of either\n             Rebif\u00ae Rebidose\u00ae or Rebiject II\u00ae devices is acceptable if they have not been using\n             them for the past 12 weeks prior to study entry and if, in the judgment of the\n             investigator, the subjects are not experienced users\n\n          -  Subject is capable of self-injecting using Rebif\u00ae Rebidose\u00ae and Rebiject II\u00ae\n             injection devices\n\n          -  Subject is willing and able to comply with the study procedures for the duration of\n             the trial\n\n          -  Signed, informed consent and Health Insurance Portability and Accountability Act\n             (HIPAA) authorization before any trial-related activities are performed\n\n          -  Female subjects of childbearing potential must have a negative pregnancy test at\n             screening to be included in the trial and must be willing to avoid pregnancy by using\n             a highly effective method of contraception\n\n          -  Outpatient status at the time of screening\n\n          -  Stable disease status without a history of surgical procedure or hospitalization\n             within 30 days prior to Study Day 1, and with no surgical intervention planned for\n             the duration of the study\n\n        Exclusion Criteria:\n\n          -  Received MS therapy other than Rebif\u00ae within the 12 weeks before screening or at any\n             time during the trial\n\n          -  Inadequate liver function and bone marrow reserve as defined in the protocol\n\n          -  Current complete transverse myelitis, bilateral optic neuritis, or neuromyelitis\n             optica\n\n          -  History of injection-site necrosis within 12 months before study entry\n\n          -  History of alcohol or drug abuse in the past year\n\n          -  Any autoimmune disorder, except for thyroid disease stable on medication\n\n          -  Subject having moderate to severe renal impairment, in the Investigator's opinion.\n\n          -  Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS\n\n          -  Participation in another clinical trial within the past 30 days or an interventional\n             trial for MS in the past 12 weeks\n\n          -  Use of high-dose steroids within 14 days of screening\n\n          -  Currently experiencing moderate to severe active inflammatory skin disease at sites\n             of expected Rebif\u00ae injections\n\n          -  History of clinically significant lipoatrophy at sites of expected Rebif\u00ae injections,\n             in the investigator's opinion\n\n          -  Current major depression or suicidal ideation or suicide attempt in the past year\n\n          -  Experiencing spasticity which in the opinion of the Investigator, could interfere\n             with self-injections\n\n          -  Pregnant or lactating\n\n          -  Inability to self-inject or visual impairment which, in the opinion of the\n             Investigator, is severe enough, even with correction, to impede the subject's\n             participation in this study\n\n          -  Upper extremity deficit which, in the opinion of the Investigator, is severe enough\n             to impede the subject's participation in this study\n\n          -  Cognitive deficit which, in the opinion of the Investigator, is severe enough to\n             impede the subject's participation in this study\n\n          -  Subject-reported reason that he/she cannot complete the 8-week study\n\n          -  Any other medical condition, which in the opinion of the Investigator makes the\n             subject unsuitable for this study\n\n          -  Known hypersensitivity to the trial treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02019550", 
            "org_study_id": "200136-573"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rebif\u00ae Rebidose\u00ae/Rebiject II\u00ae", 
                "description": "Rebif\u00ae will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week (12 injections) by using Rebif\u00ae Rebidose\u00ae self-injector device in Period 1 (4 weeks). Total treatment duration will be of 8 weeks.", 
                "intervention_name": "Rebif\u00ae Rebidose\u00ae", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Rebif\u00ae Rebidose\u00ae/Rebiject II\u00ae", 
                "description": "Subjects who will receive Rebif\u00ae by using Rebif\u00ae Rebidose\u00ae in Period 1 will be receiving Rebif\u00ae at a dose of 44 mcg subcutaneously three times a week (12 injections) by using Rebiject II\u00ae self-injector device in Period 2 (4 weeks). Total treatment duration will be of 8 weeks.", 
                "intervention_name": "Rebiject II\u00ae", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Rebiject II\u00ae/Rebif\u00ae Rebidose\u00ae", 
                "description": "Rebif\u00ae will be administered at a dose of 44 mcg subcutaneously three times a week (12 injections) by using Rebiject II\u00ae self-injector device in Period 1 (4 weeks). Total treatment duration will be of 8 weeks.", 
                "intervention_name": "Rebiject II\u00ae", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Rebiject II\u00ae/Rebif\u00ae Rebidose\u00ae", 
                "description": "Subjects who will receive Rebif\u00ae by using Rebiject II\u00ae in Period 1 will be receiving Rebif\u00ae at a dose of 44 mcg subcutaneously three times a week (12 injections) by using Rebif\u00ae Rebidose\u00ae self-injector device in Period 2 (4 weeks). Total treatment duration will be of 8 weeks.", 
                "intervention_name": "Rebif\u00ae Rebidose\u00ae", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Interferon beta 1a"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple Sclerosis, Relapsing-Remitting", 
            "Rebif\u00aeRebidose\u00ae", 
            "Rebiject II\u00ae"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Dover", 
                        "country": "United States", 
                        "state": "Delaware"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Patchogue", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plainview", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hickory", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greensburg", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif\u00ae Rebidose\u00ae and Rebiject II\u00ae Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF\u00ae 44 mcg Subcutaneously Three Times a Week", 
        "overall_contact": {
            "last_name": "US Medical Information", 
            "phone": "888-275-7376"
        }, 
        "overall_official": {
            "affiliation": "EMD Serono, Inc., Rockland MA, a subsidiary of Merck KGaA, Darmstadt, Germany", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of subjects rating the device as easy to use", 
            "safety_issue": "No", 
            "time_frame": "Up to Week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02019550"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The User Trial Questionnaire will be used to assess the ease of use, functional reliability, overall satisfaction with device attributes, convenience, use-safety and portability of the device.", 
                "measure": "Percentage of subjects rating the device based on User Trial Questionnaire (UTQ)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 4 and 8"
            }, 
            {
                "measure": "Percentage of subjects rating the device as very difficult, difficult, neither easy nor difficult, easy, or very easy", 
                "safety_issue": "No", 
                "time_frame": "Weeks 4 and 8"
            }, 
            {
                "measure": "Change from Baseline in Multiple Sclerosis International Quality of Life (MusiQoL) score at Weeks 4 and 8", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Weeks 4 and 8"
            }
        ], 
        "source": "EMD Serono", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "EMD Serono", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}